Analysis of adverse drug reactions caused by carbapenems and review of related literature

doi:10.5246/jcps.2023.10.067

Abstract

Abstract:

This study aimed to review the literature on adverse drug reactions (ADRs) caused by the clinical use of carbapenems and their effects on platelet abnormalities. We also analyzed the clinical characteristics of these cases and provided references for the safe clinical use of carbapenems. Individual cases of platelet abnormalities caused by the carbapenem drugs, including imipenem and meropenem, were collected from PubMed, Medline, the Chinese Academic Journal Full-text Database (CNKI), and the Vip Chinese Science and Technology Journal Database. The patients’ conditions (such as sex and age), diseases, and prognoses were statistically analyzed. Three cases of platelet abnormalities were observed after the clinical use of imipenem, and 17 cases were reviewed for meropenem. Among these cases, carbapenem caused 11 cases of platelet elevation and 9 cases of thrombocytopenia. The ADRs were resolved within 4–18 d after drug withdrawal and were classified as serious adverse drug reactions. Although there are limited reports of ADRs caused by carbapenems resulting in platelet abnormalities, the consequences can be serious. Therefore, in clinical practice, special attention should be given to the ADRs of carbapenems in blood, early monitoring, and timely symptomatic treatment.

Key words: Carbapenem, Thrombocytopenia, Adverse drug reactions, Literature analysis

Supporting:

Xinyu Chang, Lijuan Han, Yang Liu, Zheng Fan, Jiankun Wu. Analysis of adverse drug reactions caused by carbapenems and review of related literature[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 835-841.

Figures/Tables 4

References 31

[1]	Yan, Q.; Xia, P.Y.; Yang, F.; Lv, X.J. Clinical Pharmacotherapy·Infectious diseases. People’s Health Publishing House. 2017.
[2]	Wang, G.F.; Li, J.; Lu, J.M.; Wang, Y.; Li, Z.P. Adverse drug reactions caused by carbapenems. Eval. Anal. Drug Use Hosp. China. 2017, 6, 830–835.
[3]	Tang, C.M.; Yang, S.Y.; Zhan, Y.Y.; Chen, L. Research on adverse reaction signal mining of three carbapenems based on FAERS database. Cent. South Pharm. 2021, 19, 2576–2581.
[4]	Li, J.T.; Li, B.; Liu, X.H. Treatment analysis and literature review of a patient with thrombocytosis secondary to pulmonary abscess. Strait Pharm. J. 2019, 9, 244–246.
[5]	Li, H.X.; Dai, X.L.; Chen, X.L; Zhou, T.R. One case of meropenem-induced thrombocytopenia. Shanghai Med. Pharm. J. 2017, 23, 52–54.
[6]	Wang, Y.T.; Zhang, H.H.; Jiang, D.L.; Qi, B. Analysis of a case of thrombocytopenia. Chin. J. Lab. Diagn. 2017, 9, 1651–1652.
[7]	Wu, H.Y.; Gao, X.; Hong, X.D.; Chen, J. Clinical Pharmacist’s Pharmaceutical Intervention to A Case of Severe Thrombocytosis Caused by Meropenem in An Infant. Pharm. Today. 2015, 10, 721–723.
[8]	Ren, C.; Chen, X.; Yang, M.M.; Zhang, Y. Pharmaceutical care of ameropenem-induced thrombocytopenia patient. North. Pharm. J. 2017, 3, 370–372.
[9]	Wang, Q.; Wang, X.; Chen, X.M.; Zhang, H.F. A case report of secondary thrombocytosis caused by meropenem. Lab. Med. 2021, 1, 117–118.
[10]	Lin, H.; Li, J.L.; Wang, L. A case of thrombocytopenia caused by meropenem. China Pharm. 2008, 5, 25.
[11]	Hu, D.; Deng, A.P. Two cases of increased platelets induced by meropenem. Chin. J. Drug Appl. Monit. 2017, 2, 126–128.
[12]	Wu, Y.; Xiao, M.S. A case of severe thrombocytopenia caused by meropenem. Exp. Lab. Med. 2015, 3, 388–389.
[13]	Gan, H.Z.; Chen, Q.H.; Chen, D.Z.; Xu, Y.Y.; Wang, J.K. A case of extreme thrombocytosis caused by meropenem injection. Chin. J. Pharm. 2021, 11, 780–781.
[14]	Huang, B.K.; Li, S.P.; Wang, X.Y. A case of thrombocytopenia caused by meropenem injection. J. Pract. Gynecol. Endocrinol. 2018, 19, 181–184.
[15]	Li, Y.Y.; Zhu, Y.B. A case of thrombocytopenia caused by meropenem injection. Chin. J. Pharm. 2017, 8, 505–506.
[16]	Liu, Y.R.; He, Y.J. Thrombocytosis caused by meropenem for injection. Adv. Drug React. J. 2021, 10, 544–545.
[17]	Kashif, H.; Muhammad, S.S.; Naureen, M.; Ambreen, M.; Sidra, I. Meropenem-induced pancytopenia in a preterm neonate: a case report. J. Med. Case Reports. 2021, 15, 25.
[18]	Cachia, J.; Torpiano, P.; Pace, D. Meropenem-induced thrombocytopenia: a paediatric case. BMJ Case Rep. 2021, 14, e243443.
[19]	Huang, T.; Zhang, J.; Liu, Y.; Cao, Z.; Shi, X.K. A case of thrombocytosis induced by imipenem cilastatin sodium. Cent. South Pharm. 2019, 10, 1803–1804.
[20]	Yu, Y.C.; Gao, D.Q. Severe thrombocytopenia induced by imipenem and cilastatin sodium. Adv. Drug React. J. 2020, 11, 654–655.
[21]	Xu, J. Analysis of adverse reactions of imipenem cilastatin sodium in two cases. Med. Pharm. J. Chin. PLA. 2011, 1, 60–61.
[22]	Sun, X. Analysis of common adverse drug reactions and rational drug use in the elderly. J. Clin. Ration. Drug Use. 2017, 29, 89–90.
[23]	Wang, Z.Y.; Zhu, H.C. Study on Common Adverse Drug Reaction Reports and Rational Drug Use Intervention Measures in the Elderly. Gansu Sci. Technol. 2020, 16, 134–136.
[24]	Chen, H. Analysis of Adverse Drug Reactions and Rational Drug Use Interventions in the Elderly. China Health Nutr. 2016, 25, 318–319.
[25]	Du, L.P.; Mei, D. Pathogenesis, clinical manifestations, prevention and treatment of drug-induced thrombocytopenia. Adv. Drug React. J. 2007, 6, 414–419.
[26]	Qin, W.; Wang, X.X.; Du, W.W.; Cui, G. Research progress in drug-induced thrombocytopenia. Eval. Anal. Drug Use Hosp. China. 2017, 5, 578–579.
[27]	Yang, J.Y.; Gu, J. Research progress in the mechanism of drug-induced thrombocytopenia. Chin. J. Hosp. Pharm. 2013, 22, 1874–1877.
[28]	Zhao, X.Z.; Cui, H.G. Research progress in the classification of drug-induced immune thrombocytopenia and the diagnosis and treatment of tirofiban induced thrombocytopenia. Shandong Med. J. 2022, 33, 102–106.
[29]	Chen, C.C.; Tan, R.J.; Wang, L.S.; Zhang, Y.Y.; Hu, X.Y.; Chen, Y.Y. Clinical characteristics and risk factors of thrombocytopenia induced by fluoroquinolones. Chin. J. Pharm. 2022, 3, 306–309.
[30]	Chen, S.Y.; Li, X.; Liu, L.H.; He, X.; Ma, H.L.; Zhang, M.M. Literature analysis of drug-induced secondary thrombocytosis, Literature Analysis on Drug-induced Second Thrombocytosis. China Pharm. 2017, 9, 1633–1635.
[31]	Pei, Y.Y.; Hao, J.H.; Duan, W.Q.; Zheng, Y.J.; Zhao, M.; Yang, L.P. Severe and lethal adverse reactions of linezolid—a summary analysis of case reports. J. Chin. Pharm. Sci. 2022, 31, 153–161.